ALK and non-small cell lung carcinoma: In the ALCHEMIST trial (NCT02194738), patients with stage IB–IIIA resected ALK-rearranged NSCLC are randomized to either crizotinib or observation after completion of standard therapy, including chemotherapy and radiotherapy, when indicated.